Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).
Azpilikueta A, Bolaños E, Lang V, Labiano S, Aznar MA, Etxeberria I, Teijeira A, Rodriguez-Ruiz ME, Perez-Gracia JL, Jure-Kunkel M, Zapata JM, Rodriguez MS, Melero I. Azpilikueta A, et al. Among authors: melero i. Oncoimmunology. 2017 Sep 21;7(1):e1368605. doi: 10.1080/2162402X.2017.1368605. eCollection 2017. Oncoimmunology. 2017. PMID: 29296520 Free PMC article.
Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication.
Huarte E, Larrea E, Hernández-Alcoceba R, Alfaro C, Murillo O, Arina A, Tirapu I, Azpilicueta A, Hervás-Stubbs S, Bortolanza S, Pérez-Gracia JL, Civeira MP, Prieto J, Riezu-Boj JI, Melero I. Huarte E, et al. Among authors: melero i. Mol Ther. 2006 Jul;14(1):129-38. doi: 10.1016/j.ymthe.2006.02.015. Epub 2006 Apr 19. Mol Ther. 2006. PMID: 16627004 Free article.
[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C, Murillo O, Tirapu I, Azpilicueta A, Huarte E, Arina A, Arribillaga L, Pérez-Gracia JL, Bendandi M, Prieto J, Lasarte JJ, Melero I. Alfaro C, et al. Among authors: melero i. An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. doi: 10.4321/s1137-66272006000100007. An Sist Sanit Navar. 2006. PMID: 16670731 Free article. Review. Spanish.
The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.
Arina A, Murillo O, Hervás-Stubbs S, Azpilikueta A, Dubrot J, Tirapu I, Huarte E, Alfaro C, Pérez-Gracia JL, González-Aseguinolaza G, Sarobe P, Lasarte JJ, Jamieson A, Prieto J, Raulet DH, Melero I. Arina A, et al. Among authors: melero i. Int J Cancer. 2007 Sep 15;121(6):1282-95. doi: 10.1002/ijc.22795. Int J Cancer. 2007. PMID: 17520674 Free article.
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, Palazon A, Hervas-Stubbs S, Gurpide A, Lopez-Picazo JM, Grande-Pulido E, Melero I, Perez-Gracia JL. Alfaro C, et al. Among authors: melero i. Br J Cancer. 2009 Apr 7;100(7):1111-9. doi: 10.1038/sj.bjc.6604965. Epub 2009 Mar 10. Br J Cancer. 2009. PMID: 19277038 Free PMC article.
374 results